首页> 美国卫生研究院文献>eLife >Adequate statistical power in clinical trials is associated with the combination of a male first author and a female last author
【2h】

Adequate statistical power in clinical trials is associated with the combination of a male first author and a female last author

机译:在临床试验中适当的统计能力与男性第一作者和女性最后作者的组合有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clinical trials have a vital role in ensuring the safety and efficacy of new treatments and interventions in medicine. A key characteristic of a clinical trial is its statistical power. Here we investigate whether the statistical power of a trial is related to the gender of first and last authors on the paper reporting the results of the trial. Based on an analysis of 31,873 clinical trials published between 1974 and 2017, we find that adequate statistical power was most often present in clinical trials with a male first author and a female last author (20.6%, 95% confidence interval 19.4-21.8%), and that this figure was significantly higher than the percentage for other gender combinations (12.5-13.5%; P<0.0001). The absolute number of female authors in clinical trials gradually increased over time, with the percentage of female last authors rising from 20.7% (1975-85) to 28.5% (after 2005). Our results demonstrate the importance of gender diversity in research collaborations and emphasize the need to increase the number of women in senior positions in medicine.
机译:临床试验对于确保药物新疗法和新疗法的安全性和有效性至关重要。临床试验的关键特征是其统计能力。在这里,我们调查了试验的统计能力是否与报告试验结果的论文的第一作者和最后作者的性别有关。根据1974年至2017年间发表的31,873项临床试验的分析,我们发现在临床试验中,男性为第一作者,女性为最后作者通常具有足够的统计能力(20.6%,95%置信区间19.4-21.8%) ,并且这个数字明显高于其他性别组合的百分比(12.5-13.5%; P <0.0001)。随着时间的推移,临床试验中女性作者的绝对数量逐渐增加,最后女性作者的百分比从20.7%(1975-85)增加到28.5%(2005年之后)。我们的结果证明了性别多样性在研究合作中的重要性,并强调需要增加担任医学高级职位的妇女人数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号